Lancet Oncology

Drug targeting BRAF mutation slows thyroid cancer, too

In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine ...

Jul 23, 2016
popularity27 comments 0

Expanding global access to radiotherapy

Queen's University researcher Timothy Hanna has co-authored a Lancet Oncology study that suggests as many as 90 per cent of people in low-income countries lack access to radiotherapy treatment. The lack of access to radiotherapy ...

Oct 07, 2015
popularity8 comments 0